Avricore Health Inc - Asset Resilience Ratio
Avricore Health Inc (AVCR) has an Asset Resilience Ratio of 0.75% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Avricore Health Inc strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2008–2024)
This chart shows how Avricore Health Inc's Asset Resilience Ratio has changed over time. See net asset quality index of Avricore Health Inc to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Avricore Health Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Avricore Health Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 0% |
| Short-term Investments | CA$10.00K | 0.75% |
| Total Liquid Assets | CA$10.00K | 0.75% |
Asset Resilience Insights
- Limited Liquidity: Avricore Health Inc maintains only 0.75% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Avricore Health Inc Industry Peers by Asset Resilience Ratio
Compare Avricore Health Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fleury S.A.
SA:FLRY3 |
Diagnostics & Research | 16.06% |
|
Wuhan Thalys Med Tech Co Ltd
SHG:603716 |
Diagnostics & Research | 0.12% |
|
Spectral Med Inc
TO:EDT |
Diagnostics & Research | 11.67% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Genetic Signatures Ltd
AU:GSS |
Diagnostics & Research | 60.91% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Annual Asset Resilience Ratio for Avricore Health Inc (2008–2024)
The table below shows the annual Asset Resilience Ratio data for Avricore Health Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.44% | CA$10.00K ≈ $7.23K |
CA$2.30 Million ≈ $1.66 Million |
+0.04pp |
| 2023-12-31 | 0.39% | CA$10.00K ≈ $7.23K |
CA$2.54 Million ≈ $1.84 Million |
+0.00pp |
| 2022-12-31 | 0.39% | CA$10.00K ≈ $7.23K |
CA$2.57 Million ≈ $1.86 Million |
-13.20pp |
| 2021-12-31 | 13.59% | CA$310.00K ≈ $224.25K |
CA$2.28 Million ≈ $1.65 Million |
-75.35pp |
| 2008-12-31 | 88.94% | CA$1.58 Million ≈ $1.15 Million |
CA$1.78 Million ≈ $1.29 Million |
-- |
About Avricore Health Inc
Avricore Health Inc. engages in the health data and point-of-care technologies business. It provides HealthTab, a turnkey point-of-care testing platform for pharmacies that can test up to 27 biomarkers on the spot for screening and managing chronic conditions, such as diabetes. The company was formerly known as Vanc Pharmaceuticals Inc. and changed its name to Avricore Health Inc. in October 2018… Read more